Understanding Coloplast A/S Share Option Allocation Strategy
Report on Executive Transactions in Coloplast Securities
In adherence to Market Abuse Regulation article 19, Coloplast A/S is mandated to disclose transactions that involve executives and their related parties with respect to shares and associated securities. This report specifically focuses on the allocation of share options.
For comprehensive insights, readers can refer to Coloplast’s Remuneration Policy, which outlines how executive compensation is structured and the rationale behind share allocations.
Details of Executives Involved
Two key executives have been highlighted in the recent allocation of share options:
Kristian Villumsen
Kristian Villumsen serves as the President and CEO of Coloplast. His leadership role places him at the forefront of strategic decisions impacting the company's growth and financial health. His initial notification regarding the allocation of share options signifies a pivotal moment in his executive journey.
Anders Lonning-Skovgaard
Serving as the Executive Vice President and CFO, Anders plays an integral role in shaping Coloplast’s financial strategies. His involvement in share option allocations reflects the company’s commitment to aligning executive incentives with shareholder value.
Transaction Insights
Coloplast A/S allocated share options that pertain specifically to B shares, identified with the ISIN: DK0060448595. The nature of these transactions is classified as share option allocations, with particular interest surrounding the price and volume.
Details include:
- Price: DKK 0.00
- Volume: 73,690 share options allocated to Kristian Villumsen
- Volume: 37,511 share options allocated to Anders Lonning-Skovgaard
These allowances demonstrate Coloplast’s forward-thinking approach, prioritizing long-term growth potential for its executives while cultivating shareholder trust in their leadership.
Transaction Date and Venue
The share option transactions were conducted outside traditional trading venues, notably on February 4, 2025, at 12:10 UTC. This aspect highlights Coloplast’s unique handling of the option allocations, making it distinct from conventional public trading practices.
Contact Information for Inquiries
For those seeking more information regarding this announcement or the overall performance of Coloplast A/S, the following contacts are available:
Investors and Analysts Contacts
- Anders Lonning-Skovgaard, Executive Vice President, CFO
Tel. +45 4911 1111 - Aleksandra Dimovska, Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com - Simone Dyrby Helvind, Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2981
Email: dksdk@coloplast.com
Media Relations Contact
- Peter Mønster, Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Coloplast's Commitment to Healthcare Innovations
Founded on passion and ambition, Coloplast A/S has been dedicated to enhancing the lives of individuals with special healthcare needs. From its humble beginnings, it has evolved to become a leading player in sectors such as Ostomy Care and Continence Care. With innovative products that enable greater independence, Coloplast’s mission resonates deeply with its customer base.
The company continues to push boundaries, exploring new avenues to improve the quality of life for its users across the globe. Their ongoing efforts have solidified their reputation as a reliable partner in healthcare solutions, with a customer-centric approach driving their initiatives.
Frequently Asked Questions
1. What is the significance of share option allocations at Coloplast A/S?
Share option allocations are critical as they align executive compensation with the long-term interests of the company and its shareholders, encouraging executives to drive growth.
2. Who are the key executives involved in the recent transactions?
The key executives involved include Kristian Villumsen, President and CEO, and Anders Lonning-Skovgaard, Executive Vice President and CFO.
3. When were the transactions executed?
The transactions took place on February 4, 2025, at 12:10 UTC, conducted outside a trading venue.
4. Where can I find more information about Coloplast's policies?
For detailed information, you can refer to Coloplast's Remuneration Policy available on their official investor website.
5. How does Coloplast maintain its commitment to innovation?
Coloplast continually invests in research and development to introduce innovative products that meet the evolving needs of their users in various healthcare segments.
